Investments - Narrative (Details) - USD ($) $ in Thousands |
1 Months Ended | 3 Months Ended | 12 Months Ended | ||||
---|---|---|---|---|---|---|---|
Dec. 31, 2021 |
Apr. 30, 2020 |
Mar. 31, 2022 |
Mar. 31, 2021 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Dec. 31, 2020 |
|
Variable Interest Entity [Line Items] | |||||||
Cash received from sale of subsidiary | $ 12,900 | ||||||
Equity method investment, realized gain (loss) on disposal | $ 12,900 | $ 12,888 | $ 0 | $ 0 | |||
Research and development | 74,552 | $ 90,467 | $ 75,961 | ||||
Variable Interest Entity, Not Primary Beneficiary | |||||||
Variable Interest Entity [Line Items] | |||||||
Research and development | $ 15,000 | ||||||
Navitor Pharmaceuticals, Inc. | |||||||
Variable Interest Entity [Line Items] | |||||||
Agreement termination notice period | 30 days | ||||||
Threshold for development costs payments | $ 50,000 | ||||||
Navitor Pharmaceuticals, Inc. | Variable Interest Entity, Not Primary Beneficiary | |||||||
Variable Interest Entity [Line Items] | |||||||
Investments | $ 15,000 | ||||||
VIE, qualitative or quantitative information, ownership percentage | 13.00% |